FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 704600 74605 Express Mail Label Number

20. 

Other items or information: Unexecuted Declaration and Power of Attorney

January 20, 2006 Date of Orposit

Form PTO-1390-MOD (REV 10-96) U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER PA/4-33288A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 0/565455 CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE PCT/EP2004/008210 22 July 2004 (22.07.04) 23 July 2003 (23.07.03) TITLE OF INVENTION USE OF CALCITONIN IN OSTEOARTHRITIS APPLICANT(S) FOR DO/EO/US AZRIA ET AL. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 3. examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority  $\boxtimes$ 4. date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).

U.S. APPLICATION NO. (it known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.  PA/4-332							B8A				
The following fe				<del></del>					CULATIO	NS PTO USE	
								ONLY			
21. 🛭 Basi	c nationa	al fee					\$300				
22. Examination Fee											
If International preliminary examination report was prepared by USPTO										;	
and a	and all claims satisfy provisions of PCT Article 33(1)-(4)										
. All other situations											
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
	application to the USPTO as an International Searching Authority \$										
	☐ If International Search Report was prepared and provided to the Office \$400										
☐ All other situations											
TOTAL OF 21, 22 AND 23 =									900		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction											
thereof.	cu in al	eiectionic	medium). The	FIEE IS \$43U TOF EA	un auditio	Hai DU SN	eers or baper o	ıracü	UII		
Total Sheets	Extra	sheets		ch additional 50 or			RATE				
30 - 100 =		/50 =	mereor (round	d <b>up</b> to a whole nui 0	nber)	X \$	250	\$			
								\$			
Surcharge of \$130 for furnishing the oath of declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).											
CLAIMS							ATE				
Total claims 16		- 20 =	0		X \$	50	\$				
Independent cla		T CLAIM(S)	- 3 =	4		X \$ + \$	200 360	\$	800		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =								\$	1,700		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be								<del> </del>	.,		
filed (Note 37 CFR 1.9, 1.27, 1.28).								\$	4 500		
SUBTOTAL =  Processing fee of \$130 for furnishing the English translation later than								\$	1,700		
earliest claimed priority date (37 CFR 1.492(f)).								\$			
TOTAL NATIONAL FEE =									1,700		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied									Ţ.		
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +  TOTAL FEES ENCLOSED =								\$	1,700		
TOTAL FEES ENGLOSED -										e e	
									mount to refunded	\$	
<del>-</del>									charged	\$	
a. A chec	a. A check in the amount of \$ to cover the above fees is enclosed.										
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,700 to cover the above fees. A duplicate copy of this form is enclosed.											
The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
·											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
					Peter	. Waibel				<u> </u>	
	Novartis Attorney for Applicants									ĺ	
Corporate Intellectual Property Reg. No. 43,228 One Health Plaza, Building 104 (862) 778-7951											
East Hanover, NJ 07936-1080											

CALL, 1-800-222-1811 FOR PICKUP OR TRACKING OF ALL YOUR PACKAGE.

